Atacicept, Recombinant Human TACI/TNFRSF13B Protein
The product is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI, FUSION-TNFRSF13B-GAMMA-1 (TNFRSF13B(Pr30-110)(1-81)+HINGE-REGION(82-96)+CH2(97-206)+CH3(207-313).
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted proteins are stable at < -20°C for 3 months.
Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
The product contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as systemic lupus erythematosus. Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, lupus erythematosus, B-cell malignancies and multiple sclerosis. The product has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies.
Mechanism of action:
Atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as systemic lupus erythematosus. Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, lupus erythematosus, B-cell malignancies and multiple sclerosis. Atacicept has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies.
Atacicept is a synthetic protein also known as TACI (Transformed growth factor Receptor 13B) degrader. This protein can act as an effective immunomodulatory molecule by neutralizing B cell activators BAFF and APRIL to suppress the number of B cytokines and division, thus achieving the purpose of treating autoimmune diseases and other related diseases.
Atacicept is a soluble monomer molecule produced by genetic engineering that binds to a range of TNF receptor family members, including TACI, BCMA, and AFF-R, all of which are involved in the process of B cell activation, growth, and differentiation, and affect the function of B cell regulatory molecules. Atacicept can bind the binding sites of BAFF and APRIL, completely or partially blocking their biological activity. This allows B cell division and survival caused by BAFF and APRIL to be inhibited, thereby reducing inflammatory disease course and autoimmune response.
2. Mechanism and application
As a potent immunomodulatory molecule, Atacicept inhibits B cell activation, division, and survival through its neutralizing effect on BAFF and APRIL, thereby reducing inflammatory disease course and autoimmune response. In clinical applications, Atacicept is widely used to treat autoimmune diseases and related disorders. In clinical applications, Atacicept is mainly used to treat autoimmune diseases such as systemic lupus erythematosus, Sjogren's syndrome, arthritis, nephrotic syndrome, pemphigus, light chain disease, and acute lymphoblastic leukemia. Therefore, inhibiting the occurrence and progression of the disease by neutralizing these factors is a relatively effective treatment.
In general, the main mechanism of Atacicept is to inhibit the activation of B cells by degrading BAFF and APRIL. When these two factors bind to B cell receptors, they trigger B cell activation, reproduction, and differentiation, leading to an excessive immune response. Atacicept binds BAFF and APRIL to it to form an unstable complex that causes them to be degraded and cleared out of the body, which reduces the number and function of B cells to suppress the immune response and treat disease. In addition to its regulatory effect on B cells, Atacicept can also influence other immune cells, such as T cells and macrophages, through TACI and BCMA receptor-mediated signaling pathways.
As an important immunomodulatory molecule, Atacicept can inhibit the activation of B cells by degrading BAFF and APRIL, and achieve the role of treating autoimmune diseases and related diseases. Due to its broad clinical application prospects, it has received more and more attention and research.
3. Advantages and disadvantages
Atacicept is an immunomodulatory molecule that can be used to treat autoimmune diseases and other related diseases, such as rheumatoid arthritis, systemic lupus erythematosus, nephrotic syndrome, and more. Although it has been shown to have some therapeutic effects in the clinic, it still has some advantages and disadvantages.
Obvious effect: Atacicept can degrade BAFF and APRIL, thereby inhibiting B cell activation and division, reducing inflammatory course and autoimmune reaction. Clinical trials have shown that Atacicept alleviates autoimmune diseases and has a very good effect on diseases such as rheumatoid arthritis and light chain disease.
High safety: Compared with other commonly used drugs for the treatment of autoimmune diseases, Atacicept has a weak immunomodulatory ability and a mild inhibitory effect on the immune system, so the safety when used is relatively high.
Wide range of applications: Atacicept can be used to treat a variety of autoimmune diseases, with a wide range of applications, such as arthritis, nephrotic syndrome, pemphigus, and so on.
High cost: Atacicept is a high-value drug, which needs to be manufactured by genetic engineering technology, so its cost is high, resulting in a large economic burden for patients.
May lead to increased risk of infection: Since Atacicept works by inhibiting B cells, there may be an increased risk of infection, and in the weeks after stopping treatment, there may be an increased risk of infection in the short term due to its long-term inhibitory effect.
Facing FDA approval issues: Although Atacicept has been approved for sale by the European Medicines Agency, it is not approved by the FDA and is still in clinical trials and research.
4. Clinical progress
Multiple clinical trials for Atacicept are currently underway to understand its effectiveness in treating various autoimmune diseases and tumors. The results of these studies may help broaden the field of clinical application of Atacicept. At least 15 research programs targeting immune cell targeting and transformations at Atacicept are currently underway. As for FDA approval, Atacicept is currently approved and marketed in the European Union, but in the United States, it is still in clinical trials and research and has not been approved by the FDA. However, due to its successful application in the European market and its excellent therapeutic effect, Atacicept is expected to receive FDA approval in the future and become an important drug for the treatment of autoimmune diseases and other related diseases.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.